See more : Euromoney Institutional Investor PLC (ERM.L) Income Statement Analysis – Financial Results
Complete financial analysis of Reunion Neuroscience Inc. (REUN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Reunion Neuroscience Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Aarti Drugs Limited (AARTIDRUGS.BO) Income Statement Analysis – Financial Results
- ThinkSmart Limited (TSL.L) Income Statement Analysis – Financial Results
- Liberty Defense Holdings, Ltd. (LDDFF) Income Statement Analysis – Financial Results
- LNC Technology Co., Ltd (4587.TWO) Income Statement Analysis – Financial Results
- Changchun Zhiyuan New Energy Equipment Co., Ltd (300985.SZ) Income Statement Analysis – Financial Results
Reunion Neuroscience Inc. (REUN)
About Reunion Neuroscience Inc.
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 4.86M | 960.90K | 1.00K |
| Cost of Revenue | 0.00 | 9.15M | 1.54M | 9.40K |
| Gross Profit | 0.00 | -4.29M | -583.43K | -8.40K |
| Gross Profit Ratio | 0.00% | -88.27% | -60.72% | -840.30% |
| Research & Development | 12.98M | 7.31M | 3.42M | 193.19K |
| General & Administrative | 12.96M | 34.48M | 12.06M | 2.63M |
| Selling & Marketing | 0.00 | 3.23M | 1.63M | 305.71K |
| SG&A | 12.96M | 37.72M | 13.69M | 2.93M |
| Other Expenses | 2.02M | 3.71M | 1.34M | 139.98K |
| Operating Expenses | 27.96M | 48.74M | 18.45M | 3.27M |
| Cost & Expenses | 27.96M | 57.89M | 19.99M | 3.28M |
| Interest Income | 691.79K | 425.90K | 51.04K | 2.66K |
| Interest Expense | 17.73M | 1.10M | 303.30K | 22.56K |
| Depreciation & Amortization | 3.23M | 3.60M | 1.39M | 146.32K |
| EBITDA | -17.15M | -49.00M | -17.58M | -3.13M |
| EBITDA Ratio | 0.00% | -1,008.13% | -1,829.88% | -312,585.70% |
| Operating Income | -20.37M | -52.60M | -18.98M | -3.27M |
| Operating Income Ratio | 0.00% | -1,082.27% | -1,974.99% | -327,217.70% |
| Total Other Income/Expenses | -17.73M | 14.50M | -4.14M | 643.85K |
| Income Before Tax | -38.10M | -54.69M | -23.12M | -2.63M |
| Income Before Tax Ratio | 0.00% | -1,125.30% | -2,405.84% | -262,832.40% |
| Income Tax Expense | 28.12M | 1.10M | 303.30K | 22.56K |
| Net Income | -66.22M | -55.79M | -23.42M | -2.65M |
| Net Income Ratio | 0.00% | -1,147.86% | -2,437.41% | -265,088.60% |
| EPS | -5.69 | -4.83 | -3.54 | -0.35 |
| EPS Diluted | -5.69 | -4.83 | -3.54 | -0.35 |
| Weighted Avg Shares Out | 11.64M | 11.55M | 6.61M | 7.60M |
| Weighted Avg Shares Out (Dil) | 11.64M | 11.55M | 6.61M | 7.60M |
Reunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that management will...
Reunion Neuroscience Inc. (REUN) Q3 2023 Earnings Call Transcript
Reunion Neuroscience Inc. (NASDAQ:REUN ) Q3 2023 Earnings Conference Call February 14, 2023 8:30 AM ET Company Participants Edward Smith - CFO Greg Mayes - President and CEO Robert Alexander - Chief Medical Officer Nathan Bryson - Chief Scientific Officer...
Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET
TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that the Company plans...
Psychedelic Sunday: Ketamine Assisted Therapy
When will capital markets catch up to psychedelic industry? Ronan Levy, CEO and Co-Founder of Field Trip, discusses strategy behind focusing on ketamine assisted therapy.
Reunion Neuroscience, Inc. (REUN) Q2 2023 Earnings Call Transcript
Reunion Neuroscience, Inc. (NASDAQ:REUN ) Q2 2023 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Phil Carlson - IR, MD, KCSA Strategic Communications Greg Mayes - President and CEO Edward Smith - CFO Nathan Bryson - Chief...
Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday, November 14, 2022, at 8:30 A.M. ET
TORONTO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that it plans to release its...
Reunion Neuroscience to Present at Upcoming November Conferences
TORONTO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that the Company will participate in...
Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences
TORONTO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced it will participate...
Field Trip Health Ltd. (FTRP) CEO Joseph Del Moral on Q1 2023 Results - Earnings Call Transcript
Field Trip Health Ltd. (NASDAQ:FTRP ) Q1 2023 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Kathleen Heaney - KCSA Strategic Communications Ronan Levy - Chairman and Chief Executive Officer of Field Trip Health & Wellness Joseph...
Field Trip Health Ltd. (FTRP) CEO Joseph Del Moral on Q4 2022 Results - Earnings Call Transcript
Field Trip Health Ltd. (NASDAQ:FTRP ) Q4 2022 Earnings Conference Call June 30, 2022 8:30 AM ET Company Participants Kathleen Heaney - Investor Relations Joseph Del Moral - Co-Founder and Chief Executive Officer Ronan Levy - Co-Founder and Executive Chairman...
Source: https://incomestatements.info
Category: Stock Reports